GlobeNewsWire
25 Jun 2026, 10:35 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ProQR Therapeutics is conducting a registered direct offering of approximately 27.6 million ordinary shares at $1.81 per share to raise roughly $50 million. — Equity offerings typically lead to immediate share price dilution for existing stockholders.
-0.60Eli Lilly and Company is concurrently purchasing approximately 5.1 million shares to maintain its pro rata ownership stake. — Continued financial commitment from a major strategic partner like Eli Lilly provides a strong signal of institutional confidence in the company's technology.
+0.40The company intends to use the net proceeds to fund research and clinical development of its RNA editing pipeline and for working capital. — Increased cash runway allows the company to advance its clinical pipeline toward potential value-inflection milestones.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is raising approximately $50 million in capital to fund research and clinical development.
Eli Lilly is maintaining its pro rata ownership and continuing its strategic partnership with ProQR.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
11h ago
